Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Pfizer Keeps Hands On Consumer Product Wheel In Opting Against Split

Executive Summary

Pfizer didn't cite its consumer health business in announcing it will retain current structure, but best-selling Lipitor's cholesterol treatment indication is the most coveted indication yet to be available OTC.


Related Content

Consumer Business An Asset To Pfizer, A Divestment Chip To Analysts
Stronger Together: Pfizer Decides Against A Split
Pfizer Likes Consumer Business Right Where It Is, Or Eventually Could Be
Light Still On For Switches After Pfizer Pulls Plug On OTC Lipitor
Chronic Conditions Data Emphasize Need For Additional, Innovative OTCs


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts